AstraZeneca’s Covid-19 Antibody Treatment Failed to Prevent Symptoms in Exposed Persons

Top line

AstraZeneca announced Tuesday that its monoclonal antibody treatment for Covid-19 did not meet the primary goal of preventing symptoms in people who have been exposed to the coronavirus, minimizing hopes for a new therapeutic treatment for Covid-19. for unvaccinated people.

Key facts

The antibody therapy, AZD7442, reduced the risk of developing symptomatic Covid-19 by only 33% among all exposed patients, including those who tested negative after exposure, compared to a placebo, which was considered statistically insignificant, according to the company. Announced it’s a statement.

The data was obtained from the company’s phase III trials that were conducted in unvaccinated adults over 18 years of age with confirmed exposure to a person with Covid-19 in the previous eight days.

However, antibody therapy was 92% effective in preventing symptomatic Covid-19 compared to placebo in patients who tested negative after exposure, suggesting that the drug may be effective in preventing symptoms in people who still they are not infected.

The drug continues to be tested as a possible prophylaxis against Covid-19 in other trials, the company noted.

Crucial appointment

The trial’s principal investigator, Dr. Myron J. Levin, noted that the drug may be effective in preventing symptomatic Covid-19 in people who are not yet infected, adding: “While vaccination efforts against Covid- 19 have been successful, there is still a significant need for prevention and treatment options for certain populations, including those that cannot be vaccinated or those that may have an inadequate response to vaccination ”.

What to watch out for

AstraZeneca’s AZD7442 was developed with support from the US government.In March, the company announced that it had signed an agreement with the government to supply up to half a million doses of AZD7442 for $ 205 million, subject to the drug receiving emergency use authorization from the US Food and Drug Administration The company said it continues to discuss its next steps with the US government.

Key Background

While several effective vaccines have been developed to protect against Covid-19, effective drugs against the disease remain in short supply. Similar monoclonal antibody treatments developed by Regeneron Pharmaceuticals and Eli Lilly have been licensed for use in the US, but supplies of the drugs remain limited. The development of therapies that prevent symptomatic Covid-19 is essential to end the pandemic, since vaccines are not yet available to large sectors of the world’s population.

Other readings

AstraZeneca says its antibody treatment failed to prevent COVID-19 in exposed patients (Reuters)

AZD7442 trial for prevention of symptomatic covid-19 did not meet primary endpoint (Market watch)

Full coverage and live updates on Coronavirus

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top